Category: AVV Gene Therapy

  • Roche Signs a License Agreement with Dyno to Develop AVV Gene Therapy for ~$1.8B

    Shots: Dyno to receive upfront and is eligible to receive ~$1.8B milestones including development and commercial milestones along with royalties on any product emerges during the collaboration Dyno will be responsible for the design of novel AAV capsids with improved functional properties for gene therapy while Roche and Spark will conduct preclinical, clinical, and commercialization […]